What Researchers Did
Researchers in India conducted a randomized study to see if adding hyperbaric oxygen therapy (HBOT) to standard treatments could improve symptoms and reduce inflammation in patients with early-stage oral submucous fibrosis (OSMF).
What They Found
Both treatment groups showed clinical improvement, but the group receiving HBOT plus standard therapy had significantly greater reductions in burning sensation (p=0.020) and C-reactive protein (CRP) levels (p=0.033). This group also experienced more improvement in pain and mouth opening over time, although the mouth opening differences were not statistically significant between groups. No complications were reported with HBOT.
What This Means for Canadian Patients
For Canadian patients with early-stage oral submucous fibrosis, this research suggests that HBOT, when used alongside conventional therapy, could offer enhanced relief from burning sensations and pain, and help reduce inflammation. While HBOT may not reverse the underlying fibrous tissue, it could be a safe and beneficial addition to managing OSMF symptoms.
Canadian Relevance
This study was conducted in India and does not cover a Health Canada-recognized indication for hyperbaric oxygen therapy. No direct Canadian connection identified.
Study Limitations
The study indicated that HBOT did not reverse the underlying fibrotic bands, suggesting a limitation in addressing the structural progression of the condition.